| INTRODUCTION
Gastrointestinal stromal tumor (GIST) is an intriguing tumor type that keeps challenging oncologists, surgical oncologists, and pathologists. Even though they are rare malignancies, they are the most common sarcomas of the gastrointestinal tract. 1 Their malignant potential is variable, ranging from small, almost indolent lesions to fatal sarcomas. Once a poorly recognized disease, GIST has gained its own identity in the past 30 years with the identification of CD117, a product of the KIT (https://www.genenames.org/cgi-bin/gene_ symbol_report?hgnc_id=6342) proto-oncogene that led to a revolution in GIST treatment and prognosis as well, because of the development of tyrosine kinase inhibitors (TKI), which are able to block c-KIT signaling. [1] [2] [3] [4] Pathologic findings, such as tumor size and mitotic count, together with tumor location and tumor rupture, are used as prognostic factors in clinical practice, to predict recurrences and to decide postoperative treatment. [1] [2] [3] [4] [5] [6] With the observation that systemic inflammation features circulating white blood cells alterations, many researchers investigated the value of these hematological components of the systemic inflammatory response to predict patients' outcome. 7 Specifically, neutrophilia was found to be often accompanied by a relative lymphocytopenia. This relationship was studied as the neutrophil-tolymphocyte ratio (NLR), and it was found to be a simple index of systemic inflammatory response in critically ill patients, as well as an important prognostic factor in a variety of oncologic patients. [8] [9] [10] [11] Subsequently, other fractions were calculated, such as the monocyteto-lymphocyte ratio (MLR), the platelet-to-lymphocyte ratio (PLR), the neutrophil-to-white blood cell ratio (NWR), the lymphocyte-towhite blood cell ratio (LWR), the monocyte-to-white blood cell ratio (MWR), and the platelet-to-white blood cell ratio (PWR). [12] [13] [14] [15] Few articles are present in the literature that studied the prognostic significance of these biomarkers in GISTs. [16] [17] [18] [19] The aim of the current study was to investigate and compare the value of preoperative serum inflammation markers in predicting the prognosis of resected primary GISTs of all sites.
| MATERIALS AND METHODS
Demographics and clinicopathological characteristics were re- . Three patients with an active infection at blood sampling were excluded from the study. All the patients were staged with a contrast-enhanced thoracoabdominal computed tomography (CT); every case was discussed in a multidisciplinary meeting before and/or after surgery. All patients underwent surgery with curative intent, except two metastatic patients who received palliative resection for uncontrolled bleeding. The histological risk stratification of GISTs was determined using the Miettinen classification. 20 A complete macroscopic and microscopic resection was considered as R0, microscopic evidence of tumor at margins as R1, and macroscopic residual disease as R2. Postoperative morbidity included all adverse events occurring within the first 30 days after operation or during the same hospitalization. The complications were stratified according to the Clavien-Dindo classification. 21 
| Peripheral serum markers
Peripheral blood routine tests were performed within 30 days before surgery, according to our internal institutional policy. Serum NLR was calculated as the number of neutrophils divided by the number of lymphocytes. The value of PLR, MLR, LWR, NWR, PWR, and MWR, were calculated the same as the NLR.
| Follow-up
The patients were followed up based on the risk category to evaluate tumor recurrence and distant metastasis development. The follow-up included history and physical examination of all patients; high and moderate risk patients had to perform a contrast-enhanced thoracoabdominal CT; low-, very low-, and null-risk patients were controlled through contrast-enhanced abdominal CT. The frequency of the followup was every 3 months for the first 2 years, every 6 months for another 3 years, and then annually for up to 10 years in high and moderate risk patients; every 6 months for 5 years in low and very low risk patients, and once in the first year in patients with null risk.
| Statistical analysis
The primary endpoint of the study was DFS, calculated from the time of surgery to the date of the first relapse. and low serum inflammation markers were calculated by the best cut-off approach using the log-rank test, based on DFS data; for this purpose, 9 deciles dividing our cohort into 10 equal parts were used.
A multivariate analysis was conducted to adjust for possible confounders using Cox's proportional hazards model with the forward likelihood-ratio method, including sex and covariates with a P < 0.1 at the univariate analysis. The significance level was set at P < 0.05 (two-sided).
Data were processed using SPSS 21.0 software (IBM, Armonk, NY).
| RESULTS
The demographic and clinicopathological features of the 140 patients included in this study are shown in Table 1 Overall serious (Clavien-Dindo≥3) complication rate was 10.8%.
There were no perioperative deaths. CANANZI ET AL.
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| Disease-free survival analysis
Three patients with an R2 resection and 10 patients lost to follow-up,
were excluded from DFS analysis, which eventually included 127
patients. The median follow-up was 58.5 months (range, . Threeand five-year DFS were 89.7% and 86.9%; the median DFS was not reached. Fourteen (11%) cases of relapse were observed; eight patients were receiving the adjuvant therapy. The site of recurrence was peritoneum in eight patients, liver in five, and gastric stump in one.
Among the relapsed patients, 11 were high risk under Miettinenʼs Abbreviations: ASA, American society of anesthesiologists; HPF, high-power field; AFIP, Armed Forces Institute of Pathology; LWR, lymphocyte-to-white blood cell ratio; MLR, monocyte-to-lymphocyte ratio; MWR, monocyte-to-white blood cell ratio; NLR, neutrophil-to-lymphocyte ratio; NWR, neutrophil-to-white blood cell ratio; PLR, platelet-to-lymphocyte ratio; PWR, platelet-to-white blood cell ratio. (Table 4) . Patients with high levels of systemic inflammation markers had a significantly shorter DFS than patients with lower values (Figure 1 ).
The significant role of MLR and NLR in predicting the recurrence was also confirmed when analyzed as dichotomous variables on the multivariate analysis performed on the entire cohort and on the M0
and moderate-to high-risk subgroups (data not shown).
| DISCUSSION
Links between cancer and inflammation were first made in the nineteenth century, based on the observation that tumors often arose in the setting of chronic inflammation and that inflammatory cells were present in tumor samples. 8 Then, it became more and more evident that the inflammatory response plays an important role in tumor progression and metastases development. In fact, tumor-promoting inflammation and the capability of avoiding immune destruction have been included in the "new generation" of hallmarks of cancer. Abbreviations: AFIP, Armed Forces Institute of Pathology; HPF, highpower field; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-tolymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
The missing values are reported but were not used for the analysis.
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Variables All patients (127 patients)
Moderate-to high-risk patients (33 patients)
Step 1
Step 2
Step 3
Step 3 HR (95% CI) Abbreviations: CI, confidence interval; HR, hazard ratio; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; NS, non-significant; PLR, platelet-to-lymphocyte ratio.
form of systemic inflammation, has been shown to independently predict patients' outcome.
7,12,13
| Peripheral serum markers in GIST
Neutrophils are markers of acute and chronic inflammation, but also produce vascular endothelial growth factor and matrix metalloproteinase-9 which are able to induce tumor angiogenesis and progression. [23] [24] [25] The link between lymphocytes and cancer has been studied and these cells have been proved to play a critical role in the host immune response. Lymphocytosis and a high number of tumor-infiltrating lymphocytes were associated with improved prognosis and a better response to cytotoxic treatment in a variety of cancers. 26 The combination of lymphocytopenia and neutrophilia may reflect an inflammatory status where the high neutrophil count suppresses the cytolytic activity of lymphocytes, T cells, and NK cells. 16 A high monocyte count has been associated with poor prognosis in breast, colorectal, and hematological cancers. 16, [27] [28] [29] As components of the inflammation system, monocytes might directly stimulate tumor cell growth, producing proinflammatory cytokines, such as tumor necrosis factor, interleukin-1, and interleukin-6. T A B L E 4 Best cut-off approach using the log-rank test based on DFS data Abbreviations: MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio. *P < 0.05 was considered statistically significant. Log rank test: <n vs >n decile. The optimal cut-off value is reported in italics.
However, the role of the monocyte-macrophage lineage has been more extensively studied in tumor infiltrate than in peripheral blood. 16, 30, 31 Thrombocytosis is linked to poor clinical outcomes in cancer, and this could be because of platelet-mediated immunosuppression as well as metastasis development. 32 Both platelets and megakaryocytes are able to sequester tumor-derived proteins by endocytosis and protect cancer cells from immune clearance, which favors their adhesion to the endothelium, thus facilitating spreading. 33 Moreover, platelets may induce a more malignant phenotype in cancer cells characterized by enhanced migratory properties. 33, 34 There is accumulating evidence of the prognostic value of several blood cell combinations in oncologic patients. The most studied of these combinations, relatively to prognosis, is the NLR. High values of NLR are associated with bad outcomes in several tumors, including gastrointestinal, breast, lung, and urogynecological cancers, and melanoma, and sarcomas. 11, 13, 35 Peripheral blood tests are cheap and routinely performed before surgery, but few studies regarding the association between blood cell ratios and GIST prognosis can be found.
To the best of our knowledge, this is the first study to demonstrate the role of MLR as an independent prognostic factor for DFS in surgically resected GIST.
As of now, five studies are available in the literature, which demonstrated an association between high NLR and reduced DFS in patients affected by GIST. Perez et al 15 first showed that a high level of NLR was correlated with poor prognosis, followed by Kargin et al, 17 Goh et al, 10 Stotz et al, 18 and Feng et al. 16 On the other hand, the sixth study on this topic by Racz Also, the administration of preoperative and/or postoperative TKI therapy may modify the value of MLR and affect DFS.
Nevertheless, we decided to include patients who received TKI therapy, as this represents the current everyday clinical practice.
Moreover, there is no evidence that TKI in neoadjuvant setting, modifies MLR and a properly designed study would be required to test this hypothesis. However, even if this impact was demonstrated, MLR would be interpreted as being useful in the prediction of response, and not as a prognostic factor as reported in our study.
Anyway, most of the patients who received preoperative chemotherapy in our series were metastatic (seven of nine patients) and they have been excluded, as reported in the dedicated multivariate analysis.
As regards adjuvant therapy, the role of postoperative TKI in significantly reducing the recurrence, has been well established, and this could actually affect the DFS of the patients being treated.
However, the risk of relapse is not negligible also in the patients having adjuvant TKI, and hence, prognostic factors such as MLR could be helpful in this setting as well.
Indeed, the role of MLR should be investigated, especially in intermediate risk patients, as it may be useful in adapting the administration of TKI. Concerning high-risk patients, MLR could represent not only a prognostic factor per se but also a parameter to modulate the duration of treatment and the frequency of the followup controls.
The preoperative serum inflammation indices, such as MLR, NLR, and PLR, are simple and reliable independent prognostic factors for recurrence in GIST. In particular, this is the first study to demonstrate the prognostic value of MLR in this type of tumor.
The ability of MLR to predict the recurrence suggests, that it may be useful to drive the administration of adjuvant therapy, supplementing existing systems of risk estimation and improving their accuracy.
Future research is needed to identify the optimal cut-off values and to confirm in larger multicentric cohorts, the usefulness of MLR in the clinical management of GIST.
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